F9 cDNA ORF clone, Canis lupus familiaris(dog)

The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
Finn JD, Nichols TC, Svoronos N, Merricks EP, Bellenger DA, Zhou S, Simioni P, High KA, Arruda VR
Blood120(23)4521-3(2012 Nov)

Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.
Cantore A, Nair N, Della Valle P, Di Matteo M, M?trai J, Sanvito F, Brombin C, Di Serio C, D'Angelo A, Chuah M, Naldini L, Vandendriessche T
Blood120(23)4517-20(2012 Nov)

Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.
Nichols TC, Franck HW, Franck CT, De Friess N, Raymer RA, Merricks EP
Journal of thrombosis and haemostasis : JTH10(3)474-6(2012 Mar)

Successful in vivo propagation of factor IX-producing hepatocytes in mice: potential for cell-based therapy in haemophilia B.
Tatsumi K, Ohashi K, Kataoka M, Tateno C, Shibata M, Naka H, Shima M, Hisanaga M, Kanehiro H, Okano T, Yoshizato K, Nakajima Y, Yoshioka A
Thrombosis and haemostasis99(5)883-91(2008 May)

Molecular cloning of a cDNA encoding canine factor IX.
Evans JP, Watzke HH, Ware JL, Stafford DW, High KA
Blood74(1)207-12(1989 Jul)

Data indicate that factor IX (FIX)-R338L provides an attractive strategy to safely enhance the efficacy of gene therapy for hemophilia B (HB).
Title: The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.

Data indicate that the hyperactivating factor IX (FIX)-R338L mutation resulted in a robust 15-fold gain in potency and therefore provides a promising strategy to improve the efficacy, feasibility, and safety of hemophilia gene therapy.
Title: Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.

Report relative sensitivity of whole blood clotting time and activated partial thromboplastin time for the detection of factor IX.
Title: Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.

Describe proliferation of FIX-producing dog hepatocytes in mouse liver.
Title: Successful in vivo propagation of factor IX-producing hepatocytes in mice: potential for cell-based therapy in haemophilia B.